Long-term safety of spironolactone in acne: results of an 8-year followup study

J Cutan Med Surg. Nov-Dec 2002;6(6):541-5. doi: 10.1007/s10227-001-0152-4. Epub 2002 Sep 12.

Abstract

Background: Spironolactone has been used for over 20 years as an antiandrogen in the treatment of acne and hirsutism. No long-term studies of the safety of spironolactone used in this manner have been published. We present a study of the long-term safety and tolerance of spironolactone in 91 women with acne who were followed for up to 8 years.

Methods: A survey questionnaire was sent to 210 patients, and a comparison chart review of all patients to whom the survey was sent was made.

Results: Ninety-one completed surveys were analyzed, comprising 506 person-years of followup and 200 person-years of spironolactone exposure. Mean treatment length was 28.5 months (range = 0.5-122 months). During the 8-year followup period, there were no cases of serious illness attributable to spironolactone use. Side effects were present in 59% and resulted in cessation of the drug in 15%. Diuretic effect and menstrual irregularities were the most common adverse effects.

Conclusions: After 200 person-years of exposure to spironolactone and 506 person-years of followup over 8 years, no serious illnesses thought to be attributed to spironolactone were reported. The long-term use of spironolactone in the treatment of acne in women appears to be safe. Side effects, however, are common, although not usually a cause for stopping the drug.

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Data Collection
  • Diuresis / drug effects
  • Female
  • Follow-Up Studies
  • Humans
  • Menstruation Disturbances / chemically induced
  • Mineralocorticoid Receptor Antagonists / adverse effects
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Safety
  • Spironolactone / adverse effects
  • Spironolactone / therapeutic use*
  • Surveys and Questionnaires
  • Time Factors

Substances

  • Mineralocorticoid Receptor Antagonists
  • Spironolactone